Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age20-35
SponsorTanta University

About this trial

Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic complication of controlled ovarian stimulation of gonadotrophin-Stimulated ovarian cycles. It is theorized to manifest systemically as a result of vasoactive mediators like vascular endothelium growth factor (VEGF) being released from hyperstimulated ovaries. As a result, capillary permeability is increased which causes the extravasation of fluid from the intravascular compartment into the third space. The haemoconcentration which ensues results in complications such as hypercoagulability and reduced end organ perfusion.

Eligibility criteria

Qualifiers

Age between 18-38 years

Body mass index (calculated as weight in kilograms divided by the square of height in meters) < 30 kg/m2.

A long luteal protocol is used for ovarian stimulation.

Day 2 FSH <10 mIU/L and E2< 50 pg/ml

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Coasting
  • Cabergoline

Treatment groups

150 Participants
are divided into 2 treatment groups

Sponsors and collaborators